4Terashima M, Fujiwara H, Takagane A, et al. Prediction ot" sensitivity to fluoropyrirnidines by metabolic and target enzyme activities in gastriccancer[J]. Gastric Cancer, 2003,6 ( Suppl 1 ) 71 81.
5Koizumi W,Narahara H,Hara T,et al. S-1 plus cisplatin versus S-1 alone for first line treatment of advanced gastric cancer (SPIRITS trial) : a phase III trial[J]. Lancel Oncol, 2008,9 (3) 215-221.
6Kadokawa Y, Sonoda K, Nakajima S, et al. Advanced gaslric cancer in an elderly woman showing histopathologic CR after a course of s-l and CDDP combination therapy[J]. Gan To Kagaku Ryoho,2010,37(4) :711 713.
7Jeung HC,Rha SY,Im CK,et al. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advancedgastrie cancer with an evaluation of SPARC expression for personalized therapv[J]. Cancer,2011,117(10),2050-20.57.
8Yoshida K,Ninomiya M,Takakura N,et aL Phase II study of docetaxel and S 1 combination therapy for advanced or recurrent gastric eancer[J]. Clin Cancer Res, 2006, 12(11 Pt 1):3402 3407.
3Alberts S R, Cervantes A, Vande Velde C J, et al. Gastric cancer., epidemiology, , pathology and treatment [J]. Ann Cklcol, 2003, 14(suppl 2) : S31.
4Malet - MartinoM, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT,S21): a review[J].Oncologist, 2002, 7(4): 288.
5Tanaka F, Fukuse T, Wada H, et al. The history, mecha- nism and clinical use of oral 5 - fluorouraeil derivative chemotherapeutic agents[J]. Curr Pharm Biotechnol, 2000, 1 (2) : 137.
6Shirasaka T, TsukudaM, Inuyama Y, et al. New oral anticancer drug, TS- I (S- 1) from bench to clinic[Jl. Gan To Kagaku Ryoho, 2001, 28(6): 855.
7Sato A, fro T, Tomita T, et ai. Chemotherapy of gastric cancera review of clinical trials in Japan[J]. Gan To Kagaku Ryoho, 2002, 29(9): 1522.
8WASABURO K, HIROYUKIN, TAKUO H, et al. S- 1 plus eisplatin versus S- 1 alone for firstline treatment of advanced gastric cancer ( SPIRITS trial) : a phase Ⅲ trial [J] . Lancet Oncol, 2008, 9(3): 215.
